Video Consultations for Insulin Pump-Treated Type 1 Diabetes: Non-Inferior Glycemic Control with Nuanced Patient Outcomes
Posted inDiabetes & Endocrinology Internal Medicine news

Video Consultations for Insulin Pump-Treated Type 1 Diabetes: Non-Inferior Glycemic Control with Nuanced Patient Outcomes

A 52-week RCT demonstrates that video consultations achieve comparable Time in Range (TiR) to physical visits for T1D patients on insulin pumps. While the intervention improved HbA1c and treatment satisfaction, it was associated with an inferior impact on patient quality of life.
Multicomponent Nudges Significantly Boost Influenza Vaccination Rates in Primary Care: Insights from the BE IMMUNE Trial
Posted inInternal Medicine news Public Health

Multicomponent Nudges Significantly Boost Influenza Vaccination Rates in Primary Care: Insights from the BE IMMUNE Trial

The BE IMMUNE randomized trial demonstrates that combining patient text reminders, clinician EHR pended orders, and peer comparisons increases flu vaccination by 5.1 percentage points among adults aged 50 and older, highlighting the efficacy of multilevel behavioral interventions in clinical settings.
Low Potassium Levels Linked to Five-Fold Increase in Daily Atrial Fibrillation Risk: Insights from Continuous Monitoring
Posted inCardiology Internal Medicine news

Low Potassium Levels Linked to Five-Fold Increase in Daily Atrial Fibrillation Risk: Insights from Continuous Monitoring

A post hoc analysis of the LOOP study reveals that hypokalaemia is significantly associated with an increased risk of daily atrial fibrillation, particularly longer episodes. The study highlights that deviations from a patient's individual baseline potassium level are stronger predictors of AF than absolute values.
Lowering Blood Pressure in Isolated Diastolic Hypertension: Evidence Supports Risk Reduction Across All Diastolic Levels
Posted inCardiology Internal Medicine news

Lowering Blood Pressure in Isolated Diastolic Hypertension: Evidence Supports Risk Reduction Across All Diastolic Levels

A large-scale meta-analysis reveals that lowering blood pressure in patients with isolated diastolic hypertension (IDH) provides cardiovascular protection comparable to those with systolic elevations, suggesting that diastolic thresholds alone should not preclude treatment in high-risk individuals.
Beyond Standard Risk Factors: High-Sensitivity C-Reactive Protein as a Critical Driver of Cardiovascular Risk Prediction
Posted inCardiology Internal Medicine news

Beyond Standard Risk Factors: High-Sensitivity C-Reactive Protein as a Critical Driver of Cardiovascular Risk Prediction

Recent large-scale studies demonstrate that high-sensitivity C-reactive protein (hsCRP) is a potent, stable predictor of cardiovascular events, even in individuals without traditional risk factors. Despite its clinical utility in improving risk reclassification, barriers to widespread adoption in clinical practice remain.
Oral Magnesium Reduces Risk of Death and Hospitalization in Heart Failure Patients with Hypomagnesemia
Posted inCardiology Internal Medicine news

Oral Magnesium Reduces Risk of Death and Hospitalization in Heart Failure Patients with Hypomagnesemia

A large-scale study of US veterans demonstrates that oral magnesium therapy significantly improves outcomes in heart failure patients with hypomagnesemia, especially those with levels below 1.3 mg/dL. Conversely, supplementation in normomagnesemic patients may increase risks, highlighting the necessity of baseline-guided clinical intervention.
Guided Antiplatelet De-escalation Proves Safe in High Atherothrombotic Risk ACS Patients: Insights from TROPICAL-ACS
Posted inCardiology Internal Medicine news

Guided Antiplatelet De-escalation Proves Safe in High Atherothrombotic Risk ACS Patients: Insights from TROPICAL-ACS

Post-hoc analysis of the TROPICAL-ACS trial demonstrates that platelet function testing-guided de-escalation of dual antiplatelet therapy from prasugrel to clopidogrel is safe and effective in ACS patients, regardless of their atherothrombotic risk profile, offering a viable strategy for individualized care.
Colchicine for Long COVID: Randomized Trial Finds No Benefit in Functional Recovery or Inflammatory Resolution
Posted inInfectious Diseases Internal Medicine news

Colchicine for Long COVID: Randomized Trial Finds No Benefit in Functional Recovery or Inflammatory Resolution

A multi-center randomized clinical trial published in JAMA Internal Medicine demonstrates that colchicine, despite its potent anti-inflammatory properties, fails to improve 6-minute walk test distances or inflammatory markers in patients suffering from Long COVID, highlighting the complexity of the condition's pathogenesis.